Open an Account
search icon
4
NOTIFICATIONS
Best Algo trading app in India
Bigul

SEQUENT SCIENTIFIC LTD. - 512529 - Announcement under Regulation 30 (LODR)-Newspaper Publication

 Dear Sir/ Madam, This has reference to the above subject, please find enclosed copies of the newspaper advertisement for 36th AGM of the Company to be held through Video Conferencing (VC) / Other Audio Visual Means (OAVM) on September 21, 2021. The advertisement appeared in Financial Express (English language) and Mumbai Lakshadeep (Marathi language). This is also hosted on the Company's website at www.sequent.in. Kindly take the same on record.
28-08-2021
Bigul

SEQUENT SCIENTIFIC LTD. - 512529 - Announcement under Regulation 30 (LODR)-Newspaper Publication

 Dear Sir/ Madam, Pursuant to the provision of Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed copies of advertisement published on August 12,2021 in 'Financial Express' and 'Mumbai Lakshadeep' newspaper providing extracts of Unaudited Financial Results of the Company for the quarter ended June 30, 2021. Kindly take the same on record.
12-08-2021

Earnings Call for Q1FY22 of Sequent Scientific

 Conference Call with Sequent Scientific Management and Analysts on Q1FY22 Performance and Outlook. Listen to the full earnings transcript.
11-08-2021
Bigul

Q1FY22 Result Announced for Sequent Scientific Ltd.

 Revenues at Rs 3,205 Million up by 8.6%, Operating EBITDA at Rs 358 Million Commenting on the Company’s performance, Manish Gupta, Managing Director stated “The quarter gone by has indeed been the most challenging one, both from demand and execution perspective. We are pleased to report an over 15% growth in our formulations business even as our API business reported a de-growth after many quarters of consistent growth. We reported revenues of Rs 320 Crores for the quarter, reflecting a growth of 8.9% YOY on constant currency basis while the EBITDA stood at Rs 35.8 Crores excluding ESOP costs. On the business side, we are pleased with continuing strong growth in the key markets of India & LATAM, and we expect improved performance in Europe and Turkey going forward. We shall continue to invest both in expanding our footprints as well as strengthening our presence in existing markets. We expect strong recovery in our API business in the second half. Our strategy for API business continues to play out well as we continue to improve the quality of business with ever increasing contribution of regulated markets business, which now stands at 72% vs. 66% last year. Despite a slower start to the year, we stay confident and on track of achieving our financial and strategic objectives for the year.” Result PDF
11-08-2021

Sequent Scientific slips 16% on disappointing June quarter results

 Ebitda margins contracted 460 basis points to 11.2 per cent in Q1FY22 from 15.8 per cent in Q4FY21
11-08-2021
Bigul

SEQUENT SCIENTIFIC LTD. - 512529 - Financial Results For The Quarter Ended June 30, 2021

 Pursuant to Regulation 30 (read with Part A of Schedule III) and Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Board of Directors at its Meeting held today, inter-alia, considered and approved the Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2021. In this regard, kindly find enclosed the following: 1. Unaudited Consolidated Financial Results along with Independent Auditor's Review Report issued by the Statutory Auditors of the Company for the quarter ended June 30, 2021. 2. Unaudited Standalone Financial Results along with Independent Auditor's Review Report issued by the Statutory Auditors of the Company for the quarter ended June 30, 2021. 3. A copy of Press Release and Investors Presentation on Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2021.
10-08-2021
Bigul

SEQUENT SCIENTIFIC LTD. - 512529 - Board Meeting Outcome for Outcome Of Board Meeting Held On August 10, 2021, Along With Unaudited Standalone & Consolidated Financial Results And Press Release For The Quarter Ended June 30, 2021

 Pursuant to Regulation 30 (read with Part A of Schedule III) and Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Board of Directors at its Meeting held today, inter-alia, considered and approved the Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2021. In this regard, kindly find enclosed the following: 1. Unaudited Consolidated Financial Results along with Independent Auditor's Review Report issued by the Statutory Auditors of the Company for the quarter ended June 30, 2021. 2. Unaudited Standalone Financial Results along with Independent Auditor's Review Report issued by the Statutory Auditors of the Company for the quarter ended June 30, 2021. 3. A copy of Press Release and Investors Presentation on Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2021.
10-08-2021
Bigul

Sequent Scientific Ltd - 512529 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

 Dear Sir/ Madam, Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, kindly note that the Company has, as part of its investors engagement activities, scheduled a conference call with the Analysts / Investors on Wednesday, August 11, 2021 to discuss its Q1FY22 financial results. The Conference call details are enclosed.
04-08-2021
Bigul

Sequent Scientific Ltd - 512529 - Board Meeting Intimation for Intimation Of Board Meeting Under Regulation 29(1) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015

 SEQUENT SCIENTIFIC LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/08/2021 ,inter alia, to consider and approve Dear Sir/Madam, Pursuant to Regulation 29(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that the Meeting of the Board of Directors of SeQuent Scientific Limited ('the Company') is scheduled to be held on Tuesday, August 10, 2021 inter-alia, to consider and approve the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter ended June 30, 2021 as required under Regulation 33 of the Listing Regulations. Further, in continuation of our intimation dated June 30, 2021 and pursuant to Company''s Code of Conduct to Regulate, Monitor and Report Trading by Designated Persons and their Immediate Relatives, the trading window for dealing in the securities of the Company is closed from July 01, 2021 till 48 hours after the declaration of Unaudited Financial Results of the Company for the quarter ended June 30, 2021. Kindly take the above on records.
04-08-2021
Bigul

Sequent Scientific Ltd - 512529 - Compliance Under Regulation 23(9) Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015

 Dear Sir/ Madam, In terms of Regulation 23(9) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose disclosure of Related Party Transactions on a consolidated basis, in the format specified in the accounting standards for the half year ended March 31, 2021. You are requested to take the same on record.
30-07-2021
Next Page
Close

Let's Open Free Demat Account